Community Paramedic Heart Failure Management Study
This study is looking at whether having community paramedics (CPs) visit patients at home to manage their heart failure (HF) can help them stay out of the hospital and improve their overall health. CPs would visit you up to twice daily, providing care like discussing your condition with a heart failure specialist, giving IV medications such as furosemide (up to 120 mg twice daily), drawing blood for labs, and offering heart failure education. This study is for adults aged 18 and older who have been in the hospital for worsening heart failure or who need strong IV medications at home but don't need to be in the hospital. The researchers want to see if this approach reduces hospital stays and emergency room visits, and improves your quality of life over 12 months. This is an observational study, meaning researchers will watch and learn from the care provided.
- Study design
- This is an observational study involving about 75 participants. Researchers will compare the community paramedic approach to standard care.
- What's involved
- Community paramedics will visit you at home up to twice daily. These visits will include discussions with a heart failure specialist, IV placement, blood draws, heart failure education, and IV medication administration.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your health will be monitored for up to 12 months to track hospitalizations, emergency department visits, and other outcomes.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Paramedic HF Management
At a glance
Conditions
NCT06874556
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Mayo Clinic
Rochester, Minnesotano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Sara Severson, APRN, C.N.P. · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Days without HospitalizationFrom date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Number of Days without Hospitalization will be measured by the number of days a patient is not admitted to the hospital.
- Number of Days in the HospitalFrom date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Number of Days in the Hospital will be determined by a patient's length of hospital stay.
- Number of Emergency Department (ED) VisitsFrom date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Number of Emergency Department (ED) Visits will be determined by the number of ED visits per patient
- Number of HospitalizationsFrom date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Number of Hospitalizations will be determined by the number of patients that are hospitalized.
- Minnesota Living with Heart Failure Questionnaire (MLHFQ)Baseline, 31 Days
Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-question quality of life questionnaire. The scores can range from 0-105, with a higher score reflecting a worse quality of life
- Number of patients to comply with the guideline-directed medical therapy (GDMT)From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Number of patients to comply with the guideline-directed medical therapy (GDMT) will be measured through medical record reviews to determine changes in adherence rates to prescribed HF medications and therapies.